Lenzumestrocel

N/A

Report date: 2023/09/05 14:57:55

Base Information

Drug NameLenzumestrocel
Drug Alias NameHYNRCS-Allo伦迈托赛Allogeneic bone marrow-derived mesenchymal stem cells (ALS)HLA-haplo Matched Allogenic Bone Marrow Derived Stem CellLenzumestrocel +[7] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsAmyotrophic Lateral Sclerosis
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2014/07/01
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCorestem Inc
China Registration ClassN/A

Develop Information

Active CompaniesCorestem Inc
Inactive CompaniesCorestemchemon Inc
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A